Furthermore, a report demonstrated that the activator of PPARA, PPARD, and PPARG is of great anti-obesity therapeutics due to the regulation of fat and gluconeogenesis [41]. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.